Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 93.4 USD 0.9% Market Closed
Market Cap: 116.4B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Gilead Sciences Inc
Change in Deffered Taxes

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gilead Sciences Inc
Change in Deffered Taxes Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Deffered Taxes CAGR 3Y CAGR 5Y CAGR 10Y
Gilead Sciences Inc
NASDAQ:GILD
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Deffered Taxes
-$2.1B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Change in Deffered Taxes
-$1.5B
CAGR 3-Years
-93%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Deffered Taxes
-$531.4m
CAGR 3-Years
N/A
CAGR 5-Years
18%
CAGR 10-Years
-13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Deffered Taxes
-$763.4m
CAGR 3-Years
N/A
CAGR 5-Years
-29%
CAGR 10-Years
-30%
No Stocks Found

Gilead Sciences Inc
Glance View

Market Cap
116.4B USD
Industry
Biotechnology
Economic Moat
None

Gilead Sciences Inc., established in 1987, embarked on its mission with a resolute focus on innovative therapeutic advancements. Nestled in the biotech haven of Foster City, California, Gilead pioneered a path that would see it evolve into a global biopharmaceutical powerhouse. The company’s nucleus is its commitment to discovering, developing, and delivering therapies for diseases with unmet medical needs. Its product portfolio reflects this dedication, notably dominated by groundbreaking advancements in antiviral therapies, particularly for HIV/AIDS, hepatitis B, and hepatitis C. Over the years, its robust research and development engine, fueled by a continual reinvestment of earnings, propelled it to the forefront of tackling complex medical challenges. Its strategic acquisitions, like the pivotal purchase of Pharmasset in 2011, underpinned its ascent in the hepatitis C treatment arena, highlighting its aptitude for identifying and integrating synergistic growth opportunities. Financially, Gilead generates its revenue through the commercialization of its pharmaceutical portfolio. It thrives on a model where its novel therapies, once developed and approved, are sold to healthcare providers and systems. The landscape of antiviral treatments, primarily the revolutionary HIV regimen and hepatitis C cures like Harvoni and Sovaldi, serves as the backbone of its revenue stream. Meanwhile, Gilead's ventures into oncology and inflammatory diseases through strategic acquisitions and partnerships aim to diversify its portfolio beyond infectious diseases. The intricate process from innovation to distribution underscores Gilead’s proficient use of its clinical expertise and market acumen to address both expanding global health needs and shareholder demands, ensuring its enduring presence in the volatile seas of the biotech industry.

GILD Intrinsic Value
94.59 USD
Undervaluation 1%
Intrinsic Value
Price

See Also

Back to Top